US FDA accepts GSK’s submission for the use of Nucala …
3 days ago · GSK plc (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) has accepted for review, data from the MATINEE study to support the regulatory review …
GSK: FDA Accepts For Review Submission For New Indication Of Nucala …
3 days ago · GSK noted that recurrent exacerbations add to pressures on healthcare systems, and the COPD -related medical costs and others cost the US healthcare system around $7 …
FDA Accepts GSK's Filing for Expanded Use of Nucala in COPD
Premium News. Economics. Housing. Earnings. Tech. Crypto. Biden Economy. Markets. Stocks: Most Actives. ... GSK’s Nucala is a monoclonal antibody with a novel mechanism of action that …
FDA to review GSK’s Nucala for COPD - Pharmaceutical Technology
2 days ago · The US Food and Drug Administration (FDA) has accepted a submission from GSK to review a new indication of Nucala (mepolizumab) as an add-on maintenance treatment for …
GSK: FDA Accepts For Review Submission For New Indication Of Nucala …
3 days ago · British drug maker GSK plc (GSK,GSK.L) announced Monday that the U.S. Food and Drug Administration has accepted for review, data from the MATINEE study to support the …
FDA accepts GSK’s re-submission for Nucala | The Pharmaletter
3 days ago · The resubmission by UK pharma major GSK (LSE: GSK) seeks authorization for Nucala as an add-on maintenance treatment for patients with chronic obstructive pulmonary …
FDA Accepts GSK's Filing for Expanded Use of Nucala in COPD
3 days ago · In the past three months, shares of GSK have plunged 21.6% compared with the industry’s 6.2% decline.. Image Source: Zacks Investment Research. More on the FDA …
GSK: applies to the FDA for an expanded indication for Nucala
3 days ago · GSK announces that the U.S. Food & Drug Administration has agreed to review data from the MATINEE study for a potential expansion of the indication for Nucala (mepoliizumab) …
GSK's Nucala and Blenrep receive regulatory boost in US and China
3 days ago · (Alliance News) - GSK PLC on Monday received a double-dose of good news with its Nucala and Blenrep products receiving positive indications from industry regulators. GSK …
GSK announces positive results from phase III trial of Nucala ...
Sep 6, 2024 · GSK plc (LSE/NYSE: GSK) today announced positive headline results of MATINEE, the phase III clinical trial evaluating Nucala (mepolizumab), a monoclonal antibody …
- Some results have been removed
Skip to content